Latest news with #JackKhattar
Yahoo
07-05-2025
- Business
- Yahoo
Supernus Pharmaceuticals's (NASDAQ:SUPN) Q1 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street's expectations in Q1 CY2025, with sales up 4.3% year on year to $149.8 million. On the other hand, the company's full-year revenue guidance of $615 million at the midpoint came in 1.6% below analysts' estimates. Its GAAP loss of $0.21 per share was significantly below analysts' consensus estimates. Is now the time to buy Supernus Pharmaceuticals? Find out in our full research report. Supernus Pharmaceuticals (SUPN) Q1 CY2025 Highlights: Revenue: $149.8 million vs analyst estimates of $147.9 million (4.3% year-on-year growth, 1.3% beat) EPS (GAAP): -$0.21 vs analyst estimates of -$0.01 (significant miss) Adjusted EBITDA: -$10.23 million vs analyst estimates of $49.3 million (-6.8% margin, significant miss) The company reconfirmed its revenue guidance for the full year of $615 million at the midpoint Operating Margin: -6.8%, down from -2.2% in the same quarter last year Market Capitalization: $1.81 billion 'Our first quarter results reflect, once again, double-digit revenue growth from our core products, as well as strong growth in adjusted operating earnings,' said Jack Khattar, President and CEO of Supernus. Company Overview With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine. Sales Growth Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Luckily, Supernus Pharmaceuticals's sales grew at a decent 10.7% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. Supernus Pharmaceuticals Quarterly Revenue Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Supernus Pharmaceuticals's recent performance shows its demand has slowed as its revenue was flat over the last two years. Supernus Pharmaceuticals Year-On-Year Revenue Growth Supernus Pharmaceuticals also breaks out the revenue for its most important segment, . Over the last two years, Supernus Pharmaceuticals's revenue was flat. This segment has outperformed its total sales during the same period, lifting the company's performance. This quarter, Supernus Pharmaceuticals reported modest year-on-year revenue growth of 4.3% but beat Wall Street's estimates by 1.3%.
Yahoo
23-04-2025
- Business
- Yahoo
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2025 after the market closes on Tuesday, May 6, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the first quarter 2025 financial and business results on Tuesday, May 6, 2025 at 4:30 p.m. ET. Following management's prepared remarks and discussion of business results, the call will be open for questions. A live webcast will be accessible in the Events & Presentations section of the Company's Investor Relations website at Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time. Following the live call, a replay will be available on the Company's Investor Relations website at The webcast will be available on the Company's website for 60 days following the live call. About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders. For more information, please visit CONTACTS: Jack A. Khattar, President and CEO Timothy C. Dec, Senior Vice President and CFOSupernus Pharmaceuticals, Inc.(301) 838-2591 or INVESTOR CONTACT:Peter VozzoICR Healthcare(443) in to access your portfolio
Reuters
18-02-2025
- Business
- Reuters
Supernus' depression treatment fails mid-stage trial, shares plunge
Feb 18 (Reuters) - Supernus Pharmaceuticals (SUPN.O), opens new tab said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its shares down 22% aftermarket. The company said the drug, SPN-820, did not show a statistically significant change compared to placebo when tested in 250 patients with treatment-resistant depression during a mid-stage trial. The patients were tested with the Montgomery-Asberg Depression Rating Scale, which measures severity of various symptoms of depression such as sadness, inner tension, reduced sleep and inability to feel. "We will continue to analyze these data and discuss the future of the program with our development partner, Navitor Pharmaceuticals," said Supernus CEO Jack Khattar. here.
